Welcome!
expansion projects
Broker's Calls
Despite lacklusture topline, this S-chip’s FY16 performance shone in more ways than one
SINGAPORE (April 5): CIMB Research is maintaining its “add” recommendation on Tianjin Zhongxin Pharmaceutical Group with an unchanged target price of US$1.30 ($1.82) as it continues to like the S-share as a “cheap proxy for China’s growing pharmac
April 05, 2017